Name | Neostigmine Bromide |
Synonyms | Juvastigmin stigmosanbromide stigmanolbromide synstigminbromide Neostigmine Bromide (3-DIMETHYLCARBAMOYLOXYPHENYL)TRIMETHYLAMMONIUM BROMIDE 3-[(Dimethylcarbamoyl)oxy]-N,N,N-trimethylanilinium bromide (3-HYDROXYPHENYL)TRIMETHYLAMMONIUM BROMIDE DIMETHYL CARBAMATE 3-[[(DIMETHYLAMINO)CARBONYL]OXY]-N,N,N-TRIMETHYLBENZAMINIUM BROMIDE 3-[[(DIMETHYLAMINO)CARBONYL]OXY]-N,N,N-TRIMETHYLBENZENAMINIUM BROMIDE |
CAS | 114-80-7 |
EINECS | 204-054-8 |
InChI | InChI=1/C12H19N2O2.BrH/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;/h6-9H,1-5H3;1H/q+1;/p-1 |
Molecular Formula | C12H19BrN2O2 |
Molar Mass | 303.2 |
Density | 1.4344 (rough estimate) |
Melting Point | 175-177°C(lit.) |
Water Solubility | 1 g/ mL |
Solubility | H2O: 1g/mL |
Appearance | powder |
Color | white |
Merck | 14,6464 |
PH | 5.2~6.2 (100g/l, 25℃) |
Storage Condition | Inert atmosphere,Room Temperature |
Refractive Index | 1.5410 (estimate) |
Physical and Chemical Properties | White crystalline powder. Melting point 167 °c (decomposition). Soluble in water (1g of the product dissolved in 1ml of water), ethanol, chloroform, almost insoluble in ether. Odorless and non-bitter. |
Use | For myasthenia gravis, Postoperative abdominal bloating and urinary retention, can also be used for supraventricular paroxysmal tachycardia, glaucoma and atropine poisoning |
Risk Codes | R26/27/28 - Very toxic by inhalation, in contact with skin and if swallowed. R36/37/38 - Irritating to eyes, respiratory system and skin. R42/43 - May cause sensitization by inhalation and skin contact. R25 - Toxic if swallowed |
Safety Description | S22 - Do not breathe dust. S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) S37/39 - Wear suitable gloves and eye/face protection S28A - |
UN IDs | UN 2811 6.1/PG 2 |
WGK Germany | 3 |
RTECS | BR3150000 |
HS Code | 29239000 |
Hazard Class | 6.1(a) |
Packing Group | II |
EPA chemical substance information | information provided by: ofmpeb.epa.gov (external link) |
Application | neostigmine bromide for myasthenia gravis, postoperative functional flatulence and urinary retention. This product can cause drug eruption, large doses can cause Nausea, Vomit, Abdominal Pain, Diarrhea, tears, salivation, severe ataxia, convulsions, Coma, unclear language, Anxiety restlessness, fear and even cardiac arrest. |
biological activity | Neostigmine Bromide is a reversible cholinesterase inhibitor. |
Target | Value |
Use | The product has reversible cholinesterase inhibitory effect, resulting in the enzymatic hydrolysis of acetylcholine, it exists in cholinergic nerve endings for a long time, and has the effect of exciting smoothing machine and skeletal muscle. It has strong effect on skeletal muscle and small miotic force, it can also be used for supraventricular paroxysmal tachycardia, as well as tube volar alkali and other excessive detoxification. Neostigmine methyl sulfate for injection. |
production method | M-dimethylaminophenol (see 15070) and dimethyl carbamoyl chloride are esterified to obtain neostigmine base, then methyl bromide into quaternary ammonium salt reaction of neostigmine bromide. Neostigmine methyl sulfate ([51-60-5]) is obtained by reacting neostigmine with dimethyl sulfate to form a quaternary ammonium salt. |
category | toxic substances |
toxicity grade | highly toxic |
Acute toxicity | intravenous-rat LD50: 0.165 mg/kg; Intravenous-mouse LD50: 0.30 mg/kg |
flammability hazard characteristics | flammable, combustion decomposition of toxic nitrogen oxides, bromide gas |
storage and transportation characteristics | The warehouse is low temperature, ventilated and dry, and stored separately from food raw materials |
extinguishing agent | water, carbon dioxide, dry powder, sand |